- Diplomat becomes distributor of recently approved cancer drug
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Janssen Biotech: Second indication won for cancer drug Imbruvica
- FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for leukemia made by Genentech, the agency said Friday.
The FDA announced the approval of Gazyva (obinutuzumab) for treating patients with previously untreated chronic lymphocytic leukemia, in combination with the chemotherapy drug chlorambucil. The drug works by helping certain cells in the immune system attack cancer cells.
CLL is a blood and bone marrow disease that usually gets worse slowly, and according to the National Cancer Institute, part of the National Institutes of Health, 15,680 people in the United States will be diagnosed with the disease, and 4,580 will die from it.